baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

SPEXIS N/ CH0106213793 /

2024-09-20 10:10:00 PM	Chg. 0.0000	Volume	Bid2024-09-20	Ask2024-09-20	Market Capitalization	Dividend Y.	P/E Ratio
0.0446CHF	0.00%	- Turnover: -	0.0446Bid Size: 10,000	-Ask Size: 11,000	2.63 mill.CHF	-	-

GlobeNewswire 04-25 Santhera Announces Preliminary Unaudited 2023 Annual Results and Provides Corporate Update Ahead of ...

GlobeNewswire 04-09 Basilea awarded CARB-X grant to develop recently acquired novel class of antibiotics

GlobeNewswire 02-13 Basilea reports strong 2023 full-year results with profitability significantly above guidance, whils...

GlobeNewswire 01-15 Basilea announces acquisition of preclinical antibiotics program from Spexis

GlobeNewswire 2023-11-01 Spexis Announces Changes to the Executive Committee

GlobeNewswire 2023-10-06 Spexis to host business update conference call on October 9, 2023

GlobeNewswire 2023-09-29 Spexis provides business update and announces financial results for the first half of 2023

GlobeNewswire 2023-09-28 Spexis announces the appointment of Gonçalo Bernardes, Ph.D., as acting Head of Chemical Biology

GlobeNewswire 2023-08-15 Spexis announces USD $2.5 million capital commitment to support the upcoming Phase 3 ColiFin® studie...

GlobeNewswire 2021-06-28 Polyphor Provides Update on the Phase III FORTRESS Study of Balixafortide in Patients With Advanced ...

GlobeNewswire 2021-06-08 Polyphor Hosting Key Opinion Leader Roundtable on Covid-19: The Need for Novel Therapies for Severe ...

GlobeNewswire 2021-06-01 Polyphor's Balixafortide Demonstrates Consistent Dual Action Anti-Viral and Anti-Inflammatory Activi...

GlobeNewswire 2021-05-18 Polyphor to Present at the UBS Global Healthcare Virtual Conference

GlobeNewswire 2021-03-05 Polyphor Announces Financial Results for the Full-Year 2020

GlobeNewswire 2021-02-26 Polyphor to Present Full-Year 2020 Financial Results on March 5

GlobeNewswire 2021-01-05 Polyphor to Take Part in Panel Discussion on Novel Oncology Targets at the LifeSci Partners 10th Ann...

GlobeNewswire 2020-12-22 Polyphor Receives Approval to Start First-in-Human Clinical Trial of Inhaled Antibiotic Murepavadin

GlobeNewswire 2020-12-14 Polyphor Announces Third Positive Data Safety Monitoring Board (DSMB) Recommendation to Continue Pha...

GlobeNewswire 2020-12-11 Polyphor Receives an Additional USD 2.3 Million Award From CARB-X to Support Ongoing Development of ...

GlobeNewswire 2020-11-24 Polyphor receives award of up to USD $3.3 million from Cystic Fibrosis Foundation to support clinica...

GlobeNewswire 2020-10-29 Polyphor completes recruitment in Phase III trial of balixafortide in metastatic breast cancer

GlobeNewswire 2020-10-14 Polyphor receives CARB-X award of up to USD 18.44 million to support development of new antibiotic p...

GlobeNewswire 2020-09-29 Polyphor Announces Closing of Fosun Pharma Licensing Agreement for balixafortide in China and Receip...

SPEXIS N/ CH0106213793 /

If you wish to receive reply to your feedback, please provide your email address.